Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

European Cardiology Review · Published 2025-09-29 · DOI 10.15420/ecr.2025.32

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.15420/ecr.2025.32

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Bruton tyrosine kinase inhibitors and cardiovascular adverse events · British Journal of Pharmacology · 2026 · Cites or is cited by this article
• The Biological Mechanisms of Frailty: Focusing on Cellular Senescence · European Cardiology Review · 2026 · Same journal
• Beyond Weight Reduction: Obesity as a Therapeutic Pivot in Cardio–Renal–Metabolic Disease and Drug Management · European Cardiology Review · 2026 · Same journal
• Calcium Channel Blockers: The Only Pharmacological Choice · European Cardiology Review · 2026 · Same journal
• Preterm Birth and Maternal Cardiovascular Risk · European Cardiology Review · 2026 · Same journal
• Experience with the Use of Quinidine in Patients with Brugada Syndrome · European Cardiology Review · 2026 · Same journal
• Cardiac Pharmacological Challenges in a Patient with Panhypopituitarism and Chronic Pericardial Effusion · European Cardiology Review · 2026 · Same journal
• Aspirin Hypersensitivity in Acute Coronary Syndrome: Literature Review and Case Report · European Cardiology Review · 2026 · Same journal
• Are the Patients We Refer for Mitraclip Receiving Optimal Medical Therapy? Experience in a Tertiary Care Hospital · European Cardiology Review · 2026 · Same journal
• Short- and Medium-term Results of Surgical versus Transcatheter Repair in Severe Tricuspid Regurgitation · European Cardiology Review · 2026 · Same journal